None listed
Conditions
Interventions
Drug : 1. Standard vs modified antiplatelet preparation
(1) On admission day, high on-treatment reactivity (HTPR) for antiplatelet drugs is evaluated with platelet function test (VerifyNow
Accumetrics, San Diego, CA).
(2) Definition of HTPR
- Aspirin resistance: >
550 of ARU
- Clopidogrel resistance: >
213 of PRU
(3) Study subject without HTPR (non-resistenace group)
Standard preparation (aspirin 100mg and clopidogrel 75mg) is maintained on the day of surgery.
(4) Study subject with HTPR
a. Random
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Standard vs modified antiplatelet preparation 1. Patients with intracranial aneurysm who plan to undergo coil embolization 2. Patient aged 20 years and more at the day of enrollment 3. Patient with less than 2 of modified Rankin scale score at the day of enrollment 4. Patient who agrees and writes out a consent form Short vs long-term dual antiplatelet therapy 1. Patients with unruptured aneurysm treated with stent-assisted coiling within 30 days at the day of enrollment 2. Patient aged 20 years or more at the day of enrollment 3. Patient who agrees and writes out a consent form
Exclusion criteria
Exclusion criteria: Standard vs modified antiplatelet preparation 1. Patient with histoy of hypersensitivity of aspirin, clopidogrel, cilostazol, or prasugrel 2. Patient with high possibility of active bleeding such as symptomatic intrcranial hemorrhage or active gastric ulcer 3. Patient with bleeding tendency or coagulopathy 4. Patient with thrombocytopenia (< 100,000/mm3 of platelet count within three months before enrollment) 5. Patient with liver disease (> 100 of AST or ALT within three months before enrollment) 6. Patient with renal disease (> 2mg/dL of serum creatinin within three months before enrollment) 7. Patient using anticoagulants 8. Patients with congestive heart failure or angina unable to be controlled 9. Patients with malignant tumor requiring treatment 10. Pregnant or breast-feeding woman 11. Patient in whom physician decision is disqualificiation Short vs long-term dual antiplatelet therapy 1. Patient with modified Rankin scale score of = 1 2. Patient with any procedural events 3. Patient who received stent-assisted coiling for fusiform or dissected aneurysm 4. Patient with side effects of aspirin or clopidogrel 5. Patient with underlying disease requiring continuous dual antiplatelet therapy over 12 months 6. Patient using anticoagulants 7. Patient with a high risk of stroke including arterial fibrillation, occlusion or stenosis of = 30% in extra- or intracranial artery, moyamoya disease, or arteriovenous malformation 8. Patient with a high possibility of active bleeding such as symptomatic intracranial hemorrhage or active gastric ulcer 9. Patient with bleeding tendency or coagulopathy 10. Patient with thrombocytopenia (< 100,000/mm3 of platelet count within three months before enrollment) 11. Patient with liver disease (> 100 of AST or ALT within 3 months before enrollment) 12. Patient with renal disease (> 2mg/dL of serum creatinine within 3 months before enrollment) 13. Patients with congestive heart failure or angina unable to be controlled 14. Patients in whom regular follow-up is unable 15. Patients with poor medical condition or life expectancy of less than 2 years 16. Pregnant or breast-feeding woman 17. Patient in whom physician decision is disqualification
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thromboembolic event | — |
Secondary
| Measure | Time frame |
|---|---|
| Unfavorable outcome;Bleeding event | — |
Countries
Korea, Republic of
Contacts
Public ContactGyojun Hwang
Seoul National University Bundang Hospital
Outcome results
None listed